WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Protalix Biotherapeutics revenue was $53.40M for the trailing 12 months ending Dec 31, 2024, with -66.7% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $18.2M, up 1.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PLX annual revenue was $53.4M, with -18.5% growth year-over-year.

PLX past revenue growth

How has PLX's revenue growth performed historically?

Company
-18.47%
Industry
497.69%
Market
20.68%
PLX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PLX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PLX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PLX revenue history

Current Revenue
$53.4M
Current Earnings
$2.9M
Current Profit Margin
5.5%

Be the first to know when PLX announces revenue.

PLX Revenue History By Year

PLX Yearly RevenuePLX RevenuePLX ChangePLX Revenue Growth
2024-12-31$53.40M-$12.10M-18.47%
2023-12-31$65.49M$17.86M+37.48%
2022-12-31$47.64M$9.29M+24.22%
2021-12-31$38.35M-$24.55M-39.03%
2020-12-31$62.90M$8.21M+15.00%
2019-12-31$54.69M$20.45M+59.73%
2018-12-31$34.24M$13.16M+62.44%
2017-12-31$21.08M$11.88M+129.13%
2016-12-31$9.20M$4.84M+110.79%
2015-12-31$4.36M$841.00k+23.87%
2014-12-31$3.52MN/AN/A
2013-12-31$0.00-$34.42M-100.00%
2012-12-31$34.42M$31.46M+1,059.84%
2011-12-31$2.97M-$8.28M-73.60%
2010-12-31$11.24M$10.86M+2,797.94%
2009-12-31$388.00kN/AN/A
2008-12-31$0.00N/AN/A
2007-12-31$0.00N/AN/A
2006-12-31$0.00-$150.00k-100.00%
2005-12-31$150.00k-$280.00k-65.12%
2004-12-31$430.00kN/AN/A
2003-12-31$0.00N/AN/A
2002-12-31$0.00N/AN/A
2001-12-31$0.00N/AN/A
2000-12-31$0.00-$3.55M-100.00%
1999-12-31$3.55M-$4.48M-55.76%
1998-12-31$8.04MN/AN/A
1997-12-31$0.00N/AN/A
1996-11-30$0.00N/AN/A

1 of 2

Protalix Biotherapeutics Revenue FAQ

What was PLX's revenue last quarter?

On Invalid Date, Protalix Biotherapeutics (NYSEMKT: PLX) reported Q4 2024 revenue of $18.22 million up 73.74% year over year. In the same quarter last year, Protalix Biotherapeutics's revenue was $10.49 million.

What was Protalix Biotherapeutics's revenue in 2024?

Protalix Biotherapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $53.40 million, a 18.47% decrease year over year.

How much does Protalix Biotherapeutics make in a day?

Based on Protalix Biotherapeutics annual revenue for the past five years, PLX makes an average of $146,728.22 per day.

What was Protalix Biotherapeutics's annual revenue growth in the past year?

As of Q2 2025, Protalix Biotherapeutics's revenue has grown -18.47% year over year. This is 516.16 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Protalix Biotherapeutics's revenue in the past year totaled $53.40 million.

How much does Protalix Biotherapeutics make in a year?

Protalix Biotherapeutics's revenue by year for the past five years is:
  • Protalix Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $53.40 million, a 18.47% decrease year over year.
  • Protalix Biotherapeutics's annual revenue for Dec 31, 2023 was $65.49 million, a 37.48% increase from 2022.
  • Protalix Biotherapeutics's annual revenue for 2022 was $47.64 million, a 24.22% increase from 2021.
  • Protalix Biotherapeutics's annual revenue for 2021 was $38.35 million, a 39.03% decrease from 2020.
  • Protalix Biotherapeutics's annual revenue for 2020 was $62.90 million, a 15% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.